Gordon W. Dewald - Concepedia

Author

Gordon W. Dewald

Also Known As

G Dewald, G W Dewald, GORDON DEWALD, GORDON W. DEWALD, GORDON W. DeWALD, Gordon DeWald, Gordon Dewald, Gordon W Dewald, Gordon W. DeWald, Gordon W. Dewald

259

Publications

18.5K

Citations

H-Index

127

Concepts

All Affiliations

Mayo Clinic Mayo Clinic in Arizona Northwestern University Dana-Farber Cancer Institute WinnMed

About

Gordon W. Dewald is an author at Mayo Clinic specializing in medicine, pathology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	75	4K
2	Health Sciences	18	21	1.3K
3	Public Health	9	9	328
4	Engineering	5	5	345
5	Natural Sciences	4	4	213

Gordon W. Dewald

160

Publications

17.2K

Citations

H-Index

Page 1

	Year	Citations
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion Alan F. List, Gordon W. Dewald, John M. Bennett, New England Journal of Medicine	2006	1.3K
Anthracycline Dose Intensification in Acute Myeloid Leukemia Hugo F. Fernández, Zhuoxin Sun, Xiaopan Yao, New England Journal of Medicine	2009	900
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial Anthony V. Moorman, Christine J. Harrison, Georgina Buck, Blood	2006	728
Clinical and biologic implications of recurrent genomic aberrations in myeloma Rafaël Fonseca, Emily Blood, Montserrat Rué, Blood	2003	658
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes David P. Steensma, Gordon W. Dewald, Terra L. Lasho, Blood	2005	466
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q Azra Raza, James A. Reeves, Eric J. Feldman, Blood	2007	422
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993) David I. Marks, Elisabeth Paietta, Anthony V. Moorman, Blood	2009	409
Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997 Ian W. Flinn, Donna Neuberg, Michael R. Grever, Journal of Clinical Oncology	2007	402
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy Animesh Pardanani, Rhett P. Ketterling, Stephanie R. Brockman, Blood	2003	394
Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997 Michael R. Grever, David Lucas, Gordon W. Dewald, Journal of Clinical Oncology	2007	353

Page 1